Prasanth Ravipati, MD
Nephrology · Omaha, NENPI 1285048256
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,700 of the $6,547 with a category attached, or 71.8%. Travere Therapeutics, Inc. accounts for 94.4% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $5,738 and has fallen 97.6% since, to $140 in 2025.
Across 26 payments — averaging $251.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$6K
- Novartis$334
- Fresenius USA Marketing, Inc.$32
Across 14 payments — averaging $26,279 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$242K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$126K
What the payments were for
- Consulting fees$4,70072%
- Travel & lodging$85913%
- Food & beverage$95415%
- Education$341%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 21 | $6,181 |
| Novartis | 3 | $334 |
| Fresenius USA Marketing, Inc. | 2 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fabhalta$251
How this compares
$6,547 in reported general payments places this provider in the 85th percentile of 60 nephrology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 20 | $15,256 |
| FarxigaDapagliflozin Propanediol | 16 | $11,266 |
| Torsemide | 50 | $687 |
| Nifedipine ErNifedipine | 15 | $490 |
| Losartan Potassium | 46 | $359 |
| Chlorthalidone | 24 | $289 |
| Tamsulosin Hcl | 23 | $197 |
| Amlodipine Besylate | 31 | $163 |
| Spironolactone | 19 | $125 |
| Carvedilol | 11 | $92 |
| Lisinopril | 13 | $58 |
| Hydrochlorothiazide | 21 | $33 |
| Potassium Chloride | 11 | $8 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Omaha
- Richard LundOmaha$378K
- Jeffrey PasserOmaha$146K
- Roslyn MannonOmaha$64K
- Troy PlumbOmaha$17K
- Eric MagliuloOmaha$9K
- Joseph BastOmaha$5K
- Stefan HemmingsOmaha$5K
- Sunil JagadeshOmaha$4K
- Judd BauerOmaha$3K
- Mohammed NazmulOmaha$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.